2. Search Result
Search Result
Results for "

matrix-degrading

" in MedChemExpress (MCE) Product Catalog:

3

Inhibitors & Agonists

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-108904
    Urokinase, Human urine

    Urokinase-type plasminogen activator; Uronase; Win 22005; Win-Kinase

    		 Ser/Thr Protease Cardiovascular Disease Cancer
    Urokinase (peptidolytic) (EC 3.4.21.73) is a serine protease, an inactive form (zymogen) of the serine protease plasminogen. Activation of plasmin triggers a proteolytic cascade reaction, which in turn participates in thrombolysis or extracellular matrix degradation, implicated in vascular disease and cancer-related research .
    Urokinase, Human urine
  • HY-114996
    ADAMTS-5 Inhibitor
    3 Publications Verification

    		 ADAMTS Inflammation/Immunology
    ADAMTS-5 Inhibitor is a potent ADAMTS-5 (aggrecanase-2) inhibitor, with an IC50 of 1.1 µM. ADAMTS-5 Inhibitor shows >40-fold functional selectivity over ADAMTS-4 (aggrecanase-1) .
    ADAMTS-5 Inhibitor
  • HY-148776
    PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 50:50)

    		Biochemical Assay Reagents Others
    PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 50:50) is a kind of poly(lactide-co-glycolide)-block-poly(ethylene glycol) (PLGA-PEG-Mal) nanoparticles. PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 50:50) has a molecular weight of 20kDA to 5.0kDA and contains a 50:50 ratio of lactic acid (LA) to glycolic acid (GA) molecules. The molecular ratio of LA to GA determines the rate of matrix degradation and protein re-release .
    PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 50:50)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: